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Abstract Common variable immune deficiency (CVID) is
a heterogeneous disease associated with ineffective produc-
tion of antibodies. It is usually diagnosed in adulthood, but a
variable proportion of children develop CVID. Early iden-
tification of patients with potentially worse prognosis may
help to avoid serious complications. The goal of this study
was to associate the clinical phenotype of patients with early
onset CVID with peripheral B-cell maturation profile. Four
color flow cytometry was used to define distribution of
peripheral B-cell subsets in 49 children with early-onset
CVID. All clinical data were extracted from medical
records. A proportion of patients demonstrated diminishing
with time total B-lymphocytes pool, beyond physiological
age-related changes. Irrespective from duration of the
follow-up period the B-cell maturation profile in individual
patients remained unchanged. We identified six different
aberrant peripheral B cell maturation profiles associated
with different clinical characteristics. Patients with an early
B-cell maturation block earlier required replacement therapy
and were at significantly greater risk of enteropathy, granu-
loma formation, cytopenia, and lymphoproliferation. B-cell
maturation inhibited at the natural effector stage was asso-
ciated with higher risk of autoimmune manifestations other
than autoimmune cytopenia. Prevalence of male patients
was observed among patients with B-cell maturation
inhibited at naïve B-cell stage. In conclusion, the diagnostic
process in patients with suspected early-onset CVID shall
include routine analysis of peripheral B-cell maturation to
provide surrogate markers identifying patients at greater risk
of developing certain complications.
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Introduction
Common variable immune deficiency (CVID) is a heteroge-
neous disease characterized by hypogammaglobulinemia, de-
fective antibody responses and recurrent infections [1, 2]. It is
associated with an increased susceptibility to autoimmune
disorders and malignancies [3–6]. The characteristic immuno-
logic defect is an ineffective differentiation of B-lymphocytes
into memory cells [7, 8] and further into plasma cells capable
of secreting all immunoglobulin types [9, 10]. CVID is usu-
ally diagnosed in second or third decade of life, but a variable
proportion of children presenting with antibody deficiency
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(AD) develop CVID during the follow-up time [11–13]. The
diagnosis in children is particularly difficult due to immuno-
logic immaturity and the persistence of transient hypogamma-
globulinemia of infancy in some children.
In attempt of identifying patients with potentially worse
prognosis several classification schemes have been devel-
oped based on abnormalities in B cell phenotyping [14–16].
Enumeration of memory cells in CVID has been proposed
as a prognostic marker of respiratory disease [8, 13, 15, 17],
splenic enlargement [8, 17], autoimmunity [8, 18], granulo-
ma formation [8, 15, 16, 18], and intestinal involvement [8].
Loss of IgM-only memory B cell subset has been correlated
with an increased risk of chronic respiratory infections po-
tentially leading to bronchiectasis [19], while the expansion
of CD21low population was associated with autoimmune
cytopenia [20].
Scarce attempts to describe features of CVID specific for
children point to differences between pediatric and adult
patients. Autoimmune cytopenia as the first symptom of
the disease [21], marked delay of diagnosis due to overlap
with common pediatric disorders [22], a substantial preva-
lence of bronchiectasis [23], sensitivity to ionizing radiation
[24], and prolonged observation required to establish the
diagnosis, are among few of these differences [25].
Considering significant age-related changes in the distri-
bution of cell subsets reflecting major B lymphocyte matu-
ration stages [26–28] it is likely that current classification
systems of CVID are not directly applicable to pediatric
population. The goal of this study was to summarize long-
term clinical observations of a well-defined population of
pediatric patients who fulfilled criteria of the European
Society for Immune Deficiencies (ESID) for probable diag-
nosis of CVID and to associate the clinical condition of
patients with peripheral B cell maturation profile [2].
Material and Methods
The study group included 49 children (18 females and 31
males, median age 10.2 years (3.1–17.5 years)) referred to
the Department of Clinical Immunology of the Children’s
Memorial Health Institute (Warsaw, Poland) between
September 1995 and September 2011 with diagnosis of
probable CVID according to ESID criteria [2].
Clinical and laboratory data of patients were collected
retrospectively from medical records. All children were
older than 2 years at first clinical manifestations and fulfilled
ESID criteria for diagnosis of probable CVID, i.e.: demon-
strated significantly reduced serum IgG, IgA and/or IgM
levels below age-matched normal values [29], poorly
responded to vaccination, and/or had low isohemaglutinin
titers. Other defined causes of hypogammaglobulinemia
have been excluded.
Clinical Data
Documented clinical data, such as history of recurrent
or chronic infections, lymphadenopathy, organomegaly,
autoimmune cytopenias and other autoimmune phenom-
ena, such as granuloma formation and enteropathy were
included in a standardized questionnaire. Date of first
symptoms associated with immune deficiency, date of
first diagnosis of aberrant immunoglobulin levels, date
of initiation of replacement therapy, as well as serum
immunoglobulin levels before replacement therapy and
any significant alteration of IgA or IgM levels thereafter
were recorded.
One of the authors has seen and followed sequentially all
patients enrolled in the study. X-linked agammaglobulinemia
(XLA) was excluded inmale patients with low B cell numbers
by evaluation of Btk expression by flow cytometry or western
blot (results not shown). Mutation analysis for any of the rare
gene defects associated with CVID such as CD19, ICOS,
BAFFR or TACI deficiency, was not performed.
B Cell Compartment Analysis
The B-cell compartment was analyzed by four color flow
cytometry using whole EDTA-K2 anticoagulated blood and
monoclonal antibodies (Table I) as described previously [30,
31]. Differential expression of CD19, IgD, IgM, CD21,
CD27, and CD38 allowed to determine five subsets reflect-
ing major B lymphocyte maturation stages: transitional
CD19+CD38++IgM++, naïve CD19+IgD+CD27−, natural
effectors CD19+IgD+CD27+, memory CD19+IgD−CD27+
B cells, and CD19+IgM−CD38++ plasmablasts (Fig. 1). A
population of CD19+CD21lowCD38low B lymphocytes rep-
resented activated B cells [32]. All results were analyzed in
context of age-matched normal values determined in the
previously described control group of 132 healthy subjects
(32 children aged 2–5 years, 30 children aged 5–10 years,
42 children aged 10–16 years, and 28 healthy young adults
older than 16 years) [30]. Results below 5th or above 95th
percentile of the age-matched normal range were considered
abnormal. All samples were run using the same methodol-
ogy and results were reviewed by the same person experi-
enced in flow cytometry. B-cell maturation profile was
determined more than once (2–6 times) in at least 3 months
interval in 36 patients from the study cohort; in the remain-
ing 13 patients only single determination was performed
(Table II).
Statistical analysis was performed with Mann–Whitney
U and Fisher exact tests.
The study was approved by an institutional review board
and carried according to the guidelines of Helsinki
Declaration. Written consent was obtained from parents
and children, if older than 16 years.
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Results
Clinical Phenotype
The clinical picture was highly variable. Recurrent respira-
tory tract infections were reported in 42 patients (85.7 %);
among them 32 patients suffered from bronchitis and/or
pneumonia, sinusitis was diagnosed in 21 patients, otitis
media in 17, and pharyngitis in seven. Bronchiectasis was
detected by high-resolution computer tomography (HRCT)
in eight patients, while pulmonary fibrosis was confirmed
by histopathology in five patients. Recurrent respiratory
system infections as a first manifestation of the immune
insufficiency were reported in 34 patients (69.4 %).
Splenomegaly was observed in 27 patients (55.1 %),
hepatomegaly in 18 patients (36.7 %), while lymphadenop-
athy affected 35 patients (71.4 %), including one patient for
whom persistent lymphadenopathy prompted the diagnostic
process. Hepatosplenomegaly alone or accompanied by
lymphadenopathy, or otitis, or autoimmune hemolytic ane-
mia (AIHA) as first manifestation of the disease were ob-
served in one patient each.
Cytopenias were reported in 17 patients (34.7 %), among
them mainly thrombocytopenia (16 patients) (32.7 %), with
isolated thrombocytopenia observed in seven patients
(14.3 %), and thrombocytopenia accompanied by leukope-
nia or autoimmune anemia—in 8 (16.3 %) and four patients
(8.2 %), respectively. One patient experienced thrombocy-
topenia, neutropenia, and anemia. Isolated thrombocytope-
nia as the first symptom of immune insufficiency was
described in three, while autoimmune hemolytic anemia in
two patients.
Other autoimmune manifestations affected six patients
(12.2 %) and included arthritis (two patients), autoimmune
Table I Composition of mono-
clonal antibodies used for
determination of B cell subsets
reflecting major peripheral
maturation stages
Tube FITC PE PerCP APC
Specificity/Clone Specificity/Clone Specificity/Clone Specificity/Clone
1 CD21/LB21 IgD/IA6-2 CD19/4G7 CD27/L128
2 IgM/G20-127 CD21/LB21 CD19/4G7 CD38/HIT2
Fig. 1 Immunophenotyping of
peripheral B lymphocytes based
on differential expression of
CD19, IgD, IgM, CD21, CD27,
CD38. B lymphocytes were
identified as cells with positive
expression of CD19 and low
side scatter (1). Recent bone
marrow emigrants (transitional
B cells) have been defined as B
lymphocytes demonstrating
high surface expression of IgM
and CD38 (2). B lymphocytes
with positive surface expression
of IgD, but lacking expression
of CD27 were identified as
naïve B cells (3). Natural
effectors expressed both IgD
and CD27 (4), while memory B
lymphocytes expressed CD27,
but did not express IgD (5).
Plasmablasts were identified as
B lymphocytes with positive
expression of CD38, but
lacking expression of IgM (6).
B lymphocytes with low
expression of CD21 and CD38
were considered as activated B
lymphocytes (7)
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thyroiditis (two patients), and autoimmune hepatitis (two
patients).
Granuloma formation was described in five patients
(10.2 %); among them one patient demonstrated granulo-
matous gingival hyperplasia as the first clinical manifesta-
tion of the immune defect. Granulomas in lungs were
confirmed by histopathology in three patients, while pres-
ence of liver granulomas was confirmed by histopathology
one patient.
Eleven patients (22.4 %) demonstrated symptoms of
enteropathy. In one patient celiac disease was diagnosed
based on biopsy results and presence of anti-gliadin anti-
bodies. Ulcerous colitis and inflammatory bowel disease
were diagnosed based on biopsy results in one and two
patients, respectively. The remaining seven patients suffered
from recurrent diarrhea which resolved after initiation of
regular immunoglobulin substitution therapy.
Humoral Immune Abnormalities
Although first clinical symptoms of immune insufficiency
were reported since median age of 4 years (2.0–16.3 years),
dysgammaglobulinemia was first detected at median age of
8.8 years (2.4–17.3 years). Median delay between first
symptoms related to immune deficiency and diagnosis of
dysgammaglobulinemia was 2.4 years (0–12.2 years).
Selective IgA deficiency as the first defect was observed
in four patients (8.2 %) at median age of 3.2 years (0.8–
15.4 years), while selectively reduced IgG levels were first
observed in ten patients at median age of 7.2 years (4.0–
17.0 years). In one patient transient hypogammaglobuline-
mia of infancy (THI) was diagnosed based on recurrent
infections accompanied by reduced IgG levels in early
childhood, that resolved spontaneously by the age of 2 years
and 4 months.
Despite periodical elevation of serum IgM levels in six
patients (12.2 %) (one boy and five girls), all currently
known gene defects causing hyper-IgM syndrome were
excluded (results not shown).
Substitution therapy due to severe clinical condition ac-
companying hypogammaglobulinemia was initiated at me-
dian age of 11.0 years (min. 3.0, max 17.6 years), with the
median interval between first observation of aberrant serum
immunoglobulin levels and initiation of replacement thera-
py of 3.6 months (0–160 months).
Alterations in B Cell Compartment
A proportion of patients for whom the B-cell profile was
determined at least three times in at least 1 year interval,
demonstrated gradual reduction of total B lymphocyte
counts. Despite lack of specific anti-B cell treatment with
anti-CD20 monoclonal antibody in five patients total B-cell
counts declined from normal to below 5th percentile of the
normal age-matched range (see Fig. 2). Irrespective from the
duration of the follow-up period and changes in total B-
lymphocyte counts, the B-cell maturation profile in individ-
ual patients remained mostly unchanged (results not shown).
We identified six different aberrant B cell peripheral
maturation profiles (Fig. 3 and Table III). Two patients with
reduced total B lymphocyte counts, normal proportion of
naïve CD19+IgD+CD27− B lymphocytes, and significantly
reduced transitional, memory, and plasmablast subsets were
assigned to group I. Immunophenotyping of B cell




Group II Group III Group IV
Number of patients 49 9 24 12
Male to female ratio 31:18 5:4a 18:6 5:7c
Median age at first clinical symptoms (years) 4.0 3.0a 5.6 4.7
Median delay between first relevant symptoms of immune deficiency and
detection of dysgammaglobulinemia (years)
2.4 1.8 2.9 3.3
Median age at initiation of replacement therapy (years) 11.0 7.4a 12.4 9.3
Excessive production of monoclonal or oligoclonal immunoglobulins (%) 14.3 % 44.4 %a 8.3 % 8.3 %
Enteropathy (%) 22.4 % 55.6 %a 12.5 % 25.0 %
Granuloma formation (%) 10.2 % 33.3 %a 0 % 15.4 %
Autoimmune cytopenia (%) 34.7 % 55.6 % 37.5 % 33.3 %
Autoimmune manifestations other than cytopenia (%) 12.2 % 11.1 % 4.2 %c 33.3 %
Combined features of cytopenia and lymphoproliferation (%) 10.2 % 44.4 %a,b 4.2 % 0 %
Combined features of cytopenia and enteropathy (%) 12.2 % 44.4 %a 4.2 % 8.3 %
a significant difference between groups II and III, b significant difference between groups II and IV, c significant difference between groups III and
IV
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Fig. 2 Despite lack of treatment with anti-CD-20 monoclonal antibody a
proportion of patients demonstrated gradual decline in total B cell counts,
beyond age-matched normal changes. Individual patients’ data are
presented as dots on box-and-whisker plots of respective age groups, with
the boxes representing the interquartile (25–75 percentiles) and the
whiskers representing the 5–95 percentiles of the age-related normal range
Fig. 3 Patients from the study cohort were assigned into six groups
reflecting the identified B-cell maturation blocks. Patients with reduced
total B cell counts with poor ability to mature beyond naïve stage, were
included in group I. Group II was composed of patients who accumu-
lated transitional B cells. Patients from group III accumulated naïve B-
cells, while in patients from group IV B lymphocytes where unable to
mature beyond natural effector B-cells. Patient from group V
demonstrated normal B-cell maturation profile, except for reduced
proportions of plasmablasts. Patient assigned to group VI demonstrated
normal B-cell maturation profile. Individual patients’ data are pre-
sented as dots on box-and-whisker plots of respective age groups, with
the boxes representing the interquartile (25–75 percentiles) and the
whiskers representing the 5–95 percentiles of the age-related normal
range
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precursors in bone marrow carried for one patient revealed
an early B cell differentiation block at transition from pre-B-
I to pre-B-II stage (results not shown).
Patients assigned to group II (n=9) demonstrated very
low relative numbers of B-lymphocytes, an accumulation of
transitional CD19+CD38++IgM++ B-cells, and significantly
reduced proportions of more mature stages. Patients
assigned to group III (n=24) demonstrated an accumulation
of B-lymphocytes at naïve stage (CD19+IgD+CD27−) of
development and significantly reduced proportions of more
mature stages (Fig. 2).
Patients assigned to group IV (n=12) accumulated natu-
ral effector B cells and demonstrated significantly reduced
proportions of older maturation stages. One patient with
normal distribution of all analyzed B-cell subsets, except
for significantly reduced proportion of plasmablasts, was
assigned to group V. One other patient with no apparent
defect in B cell maturation, as defined by the analyzed B-
cell subsets, was assigned to group VI (Fig. 2).
Due to low numbers of patients assigned to groups I, V
and VI any comparison was possible only between patients
from groups II, III, and IV (see Table II).
Variable Clinical Features Depending on B Cell Maturation
Block
We observed several differences in clinical features between
patient groups. Median age at first clinical presentation of
the immune insufficiency and at initiation of replacement
therapy was significantly lower in patients from group II
than III (3.0 vs 5.6 years, p=0.0100547 and 7.4 vs 12.4, p=
0.0057617, respectively). Other clinical features observed
more frequently in patients assigned to groups II than III
included enteropathy (55.6 % vs 12.5 %, p=0.0201), gran-
uloma formation (33.3 % vs 0 %, p=0.0154), production of
monoclonal or oligoclonal IgM (44.4 % vs 8.3 %, p=
0.0342), as well as combined features of cytopenia and
lymphoproliferation or cytopenia and enteropathy (both
44.4 % vs 4.2 %, p=0.0133). Although differences in pro-
portions of patients demonstrating autoimmune cytopenia
among the identified subgroups did not reach statistical
difference, other autoimmune manifestations were more fre-
quent among patients from group IV than III (Table II).
Significantly higher proportion of male patients was ob-
served among patients from group III (M:F=18:6), but not
in other groups.
Discussion
Common variable immune deficiency is a complex, hetero-
geneous disease, with a common feature of ineffective pro-
duction of high affinity antibodies [33]. The variability in
time of the disease onset and clinical symptoms reflects the
heterogeneity of defective mechanisms leading to abnormali-
ties in B-cell survival [34], number of circulating CD27+
memory B lymphocytes [7, 8, 13–15, 17, 35], B cell activation
after antigen receptor cross-linking [36, 37], T cell signaling
[38], and cytokine expression [3, 39]. The genetic defect has
been discovered for less than 20 % of patients [40].
The diagnostic criteria developed by the ESID first pub-
lished in 1999 [2], were changing with time to exclude
patients with other primary or secondary immune defects.
According to currently valid criteria, none of the patients
from the study cohort were able to mount T-cell dependent
or T-cell independent antibody responses, as measured by
post-vaccination response and low or lacking isohemagglu-
tinins (if applicable), respectively [41, 42]. All patients were
older than 4 years at the time of diagnosis, all criteria of
probable CVID were met, and no other cause of hypogam-
maglobulinemia was found.
The outcome of CVID depends on interplay of several
factors including sex, number of memory B lymphocytes
and baseline immunoglobulin levels [43]. The prevalence of
boys in the study group is consistent with the observation
that male patients are generally more severely affected [3,
43], but it is not clear why this prevalence was observed
only among patients demonstrating block at naïve stage of
the B cell maturation process (group III) (Table II). It is
tempting to speculate that a proportion of these patients may
suffer from an unidentified yet, X-linked form of primary
immune deficiency.
An increased susceptibility to recurrent respiratory infec-
tions, significant delay between first clinical symptoms and
hypogammaglobulinemia are common in CVID in all age
groups [1, 3, 11, 12, 17–19, 22, 44–52]. Severe complica-
tions in form of bronchiectasis and pulmonary fibrosis,
observed in a minority of the study cohort, may be probably
attributed to less cumulative respiratory tract infections than
usually experienced by adult patients [8, 11, 12, 52–56].
The mechanism of granuloma formation in CVID
patients is poorly understood [57]. Granulomatous lesions,
demonstrated by 10.2 % of the study cohort, including three
patients with features of granulomatous-lymphocytic inter-
stitial lung disease (GLILD) associated with decreased pa-
tient survival [58], were significantly more frequent among
patients with early B cell maturation defect (group II).
Similar phenotype accompanied by an expansion of B cells
at pre-naïve level has been observed in patients with chronic
granulomatous disease [59].
Patients affected with CVID have an increased ability to
produce antibodies against self-antigens, despite inability to
produce appropriate levels of antibodies to bacterial or viral
antigens [1, 3, 6, 12, 14–16, 22, 53, 60–62]. Autoimmune
phenomena have been observed in as much as 42.9 % of the
study cohort and frequently preceded other manifestations
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of the disease. In a notable proportion of patients, autoim-
mune cytopenias, especially autoimmune thrombocytopenia
(AIT), were observed as the first manifestation of the dis-
ease. The relationship between the defect in B cell matura-
tion process and AIT is not clear [61], but similar defects in
asplenic patients may indicate that spleen of CVID patients
provides an inadequate environment for efficient control of
the platelet population [63].
Gastrointestinal tract is the second most frequently af-
fected system in patients with CVID [3]. Enteropathy and
autoimmunity were significantly more frequently observed
among our patients with low B cell counts, maturation
process inhibited at transitional stage (group II), and an
expanded CD21low B cell subset possibly reflecting the
activation status, than in other subgroups of the study cohort
[13, 64, 65].
CVID may result in a panoply of other non-infectious
complications, such as persistent lymphadenopathy [1,
14–16, 26] and splenomegaly [14–16, 26]. In contrast to
previous reports, no direct association between splenomeg-
aly and significant reduction of memory B lymphocytes or
expanded CD21low population of B lymphocytes was iden-
tified [14–16]. None of the described potential B cell differ-
entiation block sites in the investigated cohort could be
associated with either of the manifestations. It is therefore
possible that both clinical phenomena result from an in-
creased frequency of infections.
B cell differentiation is a stepwise process involving
several checkpoints. Patients from groups I and II, with
low to extremely low peripheral B lymphocytes, combine
features of patients with early B cell differentiation block
similar to seen in Btk deficiency, described by Ochtrop [66].
At least one of our patients who fit into this description was
however female and therefore rather unlikely to suffer from
Btk deficiency, especially that her peripheral B cell counts
repeatedly composed 6 % to 8 % of peripheral blood lym-
phocyte (PBL) pool [67].
An increased frequency of autoimmune phenomena
among patients from group II was associated with an ex-
panded population of CD21low cells, found to be preacti-
vated, polyclonal, partially autoreactive B lymphocytes
homing to peripheral tissues [32] and a subset of B lympho-
cytes lacking surface expression of IgD and CD27, poten-
tially including CD27−IgG+ cells with suggested role in
autoimmunity [68]. The expanded subset of IgD−CD27−
cells observed in this subgroup of patients, may possibly
also contain IgA+ memory B cells [68] with potential role in
normal production of serum IgA. The accumulation of naïve
B lymphocytes observed in patients from group II may
result from an increased proliferation compensating for a
decreased bone marrow output [69, 70].
An impaired development of B-lymphocytes with natural
effector phenotype in patients from group III precludes
generation of plasma cells producing an efficient humoral
response against encapsulated bacteria. Clinically this
results in an increased susceptibility to respiratory infec-
tions. The B-cell subset composition in patients from this
group may indicate for possible defects in B-cell receptor
structure or function, including mutations in genes coding
CD19 [71, 72], CD20 [73], or CD81 [74]. Patients share
also some features of an inducible costimulator (ICOS)
deficiency, which may present both in adults and children
[75].
Defective generation of memory B cells not affecting
other cell subsets, observed in patients from group IV,
suggests a germinal center defect with normal proliferation,
manifested by an increased number of natural effector B
cells [69]. Due to extremely complex nature of the germinal
center reaction (rev. by [76]), the clinical phenotype may
result from several defects, including mutations in genes
responsible for effective cooperation of T and B lympho-
cytes in germinal centers, such as in transmembrane activa-
tor and calcium-modulator and cyclophilin ligand interactor
(TACI) [77]. This group probably encompasses also several
other defects not associated with unique aberrancy in B
lymphocyte pattern other than lack of memory B
lymphocytes.
Reduced number of plasmablasts in a patient from group
V and ineffective production of post-vaccination response
demonstrated by the patient assigned to group VI, despite
lack of an apparent block in peripheral B cell maturation,
might reflect extrafollicular, follicular or terminal post-GC
maturation defect, leading to an ineffective terminal plasma
differentiation and poor generation of long-living plasma
cells [69]. Genetic defects leading to such phenotype have
not been identified yet. Potential candidates include defec-
tive Blimp-1, known to affect the generation of long-living
plasma cells [9] or B-cell maturation antigen (BCMA),
known to affect the generation of short-living plasma cells
and serum levels of the immunoglobulins produced by these
cells [78]. Studies on significantly greater populations of
patients are necessary to find the mechanism of these
defects.
Common variable immune deficiency is generally asso-
ciated with severe reduction of post-germinal cells, with pre-
germinal cells preserved in most patients [14]. Currently
valid classification systems are based on differences in
distribution in peripheral B-cell subsets reflecting matura-
tion profiles, but referring to clearly defined cut-off values
in proportions of respective cell subsets [14–16]. A striking
observation in the long-term follow-up of a proportion of
patients from the study cohort was significant decline with
time in total B lymphocyte counts, despite lack of anti-B-
cell targeted treatment. However, even in these patients the
aberrancies in B cell profile remained stable, as reported by
Kalina [79]. In an attempt of finding surrogate markers
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identifying clinical phenotypes at higher risk of severe com-
plications, we subdivided the study group depending on aber-
rant B cell maturation profile. We identified a group of
patients, characterized by an early B cell maturation block,
with significantly earlier manifestation of the disease, earlier
need for replacement therapy, and significantly greater risk of
enteropathy, granuloma formation, cytopenia and lymphopro-
liferation. We also identified a subgroup of patients with
maturation profile inhibited at the natural effector/marginal
zone-like stage at higher risk of autoimmune manifestations
other than autoimmune cytopenia. No other significant asso-
ciation between B cell immunophenotype and clinical features
were found in the analyzed study cohort.
In summary, results of this study show that it is an oversim-
plification that pediatric patients with few or absent memory B
lymphocytes exhibit a different clinical phenotype than patients
with higher numbers of memory B lymphocytes [13]. Results
of this study present a description of the disease evolution,
including evidence that a proportion of patients may also
demonstrate diminishing with time total B-lymphocyte pool,
beyond physiological age-related changes. The diagnostic pro-
cess in recurrent manifestations of an unexplained origin in
children older than 4 years, especially cytopenia, autoimmune
or inflammatory process of unknown origin, shall therefore
include routine periodical measurement of serum immunoglo-
bulins and analysis of B cell phenotype to prevent incorrect
treatment and development of further complications.
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